Safe, Proven Results with GLP-1 Injections: Semaglutide and Tirzepatide (GLP-1 medications) are clinically proven to reduce hunger, improve insulin sensitivity, and support sustainable fat loss
If you have Medicare or Medicaid Check Lilly Cares Patient Assistance
Important limitations of the current evidence include: Most trials have been relatively small and of short duration (typically 816 weeks) Study quality varies, with some trials lacking robust blinding or having high dropout rates Publication bias may exist, with negative studies less likely to be published Long-term safety and efficacy data beyond three months are scarce Few studies have been conducted in Western populations or UK healthcare settings The National Institute for Health and Care Excellence (NICE) does not include berberine in its guidelines for diabetes management (NG28), reflecting the lack of sufficient high-quality evidence to support its routine use
It gained approval in 2017 but has surged in popularity recently due to the medications ability to help with weight loss
Some patients may notice reduced hunger and increased satiety relatively early in treatment, while others require several weeks at therapeutic doses before experiencing significant appetite changes
Note that using Semaglutide with another medicine that lowers blood sugar, such as sulfonylurea or insulin, increases the risk
